Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

依西酞普兰 雷波西汀 舍曲林 文拉法辛 西酞普兰 氟西汀 度洛西汀 帕罗西汀 氟伏沙明 安非他酮 米氮平 医学 药理学 心理学 抗抑郁药 内科学 精神科 再摄取抑制剂 焦虑 血清素 替代医学 受体 病理 戒烟
作者
Andrea Cipriani,Toshi A. Furukawa,Georgia Salanti,John Geddes,Julian P. T. Higgins,Rachel Churchill,Norio Watanabe,Atsuo Nakagawa,Ichiro M Omori,Hugh McGuire,Michele Tansella,Corrado Barbui
出处
期刊:The Lancet [Elsevier BV]
卷期号:373 (9665): 746-758 被引量:1617
标识
DOI:10.1016/s0140-6736(09)60046-5
摘要

Conventional meta-analyses have shown inconsistent results for efficacy of second-generation antidepressants. We therefore did a multiple-treatments meta-analysis, which accounts for both direct and indirect comparisons, to assess the effects of 12 new-generation antidepressants on major depression.We systematically reviewed 117 randomised controlled trials (25 928 participants) from 1991 up to Nov 30, 2007, which compared any of the following antidepressants at therapeutic dose range for the acute treatment of unipolar major depression in adults: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine. The main outcomes were the proportion of patients who responded to or dropped out of the allocated treatment. Analysis was done on an intention-to-treat basis.Mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine (odds ratios [OR] 1.39, 1.33, 1.30 and 1.27, respectively), fluoxetine (1.37, 1.32, 1.28, and 1.25, respectively), fluvoxamine (1.41, 1.35, 1.30, and 1.27, respectively), paroxetine (1.35, 1.30, 1.27, and 1.22, respectively), and reboxetine (2.03, 1.95, 1.89, and 1.85, respectively). Reboxetine was significantly less efficacious than all the other antidepressants tested. Escitalopram and sertraline showed the best profile of acceptability, leading to significantly fewer discontinuations than did duloxetine, fluvoxamine, paroxetine, reboxetine, and venlafaxine.Clinically important differences exist between commonly prescribed antidepressants for both efficacy and acceptability in favour of escitalopram and sertraline. Sertraline might be the best choice when starting treatment for moderate to severe major depression in adults because it has the most favourable balance between benefits, acceptability, and acquisition cost.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
12334完成签到,获得积分10
1秒前
2秒前
随机游动完成签到,获得积分10
7秒前
9秒前
qingsong完成签到,获得积分10
9秒前
mjt完成签到,获得积分10
11秒前
tony完成签到,获得积分10
12秒前
12秒前
万能图书馆应助vivia采纳,获得10
15秒前
mjt发布了新的文献求助10
15秒前
silent完成签到,获得积分10
18秒前
痕迹发布了新的文献求助10
18秒前
qingsong关注了科研通微信公众号
25秒前
Rez完成签到,获得积分10
27秒前
28秒前
29秒前
RUHUAN完成签到,获得积分10
30秒前
Akim应助朴实幼荷采纳,获得10
30秒前
金葡菌发布了新的文献求助10
32秒前
Xtay完成签到 ,获得积分10
34秒前
雪雪完成签到 ,获得积分10
35秒前
36秒前
JamesPei应助kkkkllll采纳,获得30
39秒前
金葡菌完成签到,获得积分20
42秒前
42秒前
没烦恼发布了新的文献求助10
43秒前
43秒前
tomorrow完成签到 ,获得积分10
45秒前
vivia发布了新的文献求助10
47秒前
玖瑶完成签到,获得积分20
48秒前
Jasper应助千秋梧采纳,获得10
50秒前
Ava应助段段采纳,获得10
50秒前
50秒前
vivia完成签到,获得积分10
53秒前
53秒前
太阳完成签到,获得积分10
54秒前
wyx完成签到 ,获得积分10
56秒前
东方千筹完成签到,获得积分20
57秒前
jiesenya完成签到,获得积分10
57秒前
太阳发布了新的文献求助10
59秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Production Logging: Theoretical and Interpretive Elements 3000
CRC Handbook of Chemistry and Physics 104th edition 1000
Izeltabart tapatansine - AdisInsight 600
Introduction to Comparative Public Administration Administrative Systems and Reforms in Europe, Third Edition 3rd edition 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
Individualized positive end-expiratory pressure in laparoscopic surgery: a randomized controlled trial 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3761721
求助须知:如何正确求助?哪些是违规求助? 3305481
关于积分的说明 10134256
捐赠科研通 3019495
什么是DOI,文献DOI怎么找? 1658190
邀请新用户注册赠送积分活动 791974
科研通“疑难数据库(出版商)”最低求助积分说明 754751